Screener
Sionna Therapeutics SION EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Sionna Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033876
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other income | — | 177 |
| Total other income | 2,820 | 3,177 |
| Net loss | $(26,779) | $(16,482) |
| Net loss per share, basic and diluted | $(0.60) | $(0.62) |
| Weighted-average common shares outstanding, basic and diluted | 44,921,984 | 26,596,059 |
| Comprehensive loss: | ||
| Net loss | $(26,779) | $(16,482) |
| Unrealized loss on marketable securities | (624) | (67) |
Item 1. Financial Statements
FAQ
- What is Sionna Therapeutics's EPS (diluted)?
- Sionna Therapeutics (SION) reported EPS (diluted) of -$0.60 in Q1 2026.
- How has Sionna Therapeutics's EPS (diluted) changed year-over-year?
- Sionna Therapeutics's EPS (diluted) increased by 3.2% year-over-year, from -$0.62 to -$0.60.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Sionna Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude